Chad M Cohen is Chief Financial Officer of Adaptive Biotechnologies Corp. Currently has a direct ownership of 21,604 shares of ADPT, which is worth approximately $114,717. The most recent transaction as insider was on Dec 22, 2021, when has been sold 10,000 shares (Common Stock) at a price of $30.0 per share, resulting in proceeds of $300,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 21.6K
0% 3M change
0% 12M change
Total Value Held $114,717

Chad M Cohen Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 22 2021
SELL
Open market or private sale
$300,000 $30.0 p/Share
10,000 Reduced 31.64%
21,604 Common Stock
Dec 22 2021
BUY
Exercise of conversion of derivative security
$72,700 $7.27 p/Share
10,000 Added 24.04%
31,604 Common Stock
Nov 10 2021
SELL
Open market or private sale
$169,650 $33.93 p/Share
5,000 Reduced 18.79%
21,604 Common Stock
Nov 10 2021
BUY
Exercise of conversion of derivative security
$36,350 $7.27 p/Share
5,000 Added 15.82%
26,604 Common Stock
Nov 09 2021
SELL
Open market or private sale
$180,150 $36.03 p/Share
5,000 Reduced 18.79%
21,604 Common Stock
Nov 09 2021
BUY
Exercise of conversion of derivative security
$36,350 $7.27 p/Share
5,000 Added 15.82%
26,604 Common Stock
Oct 06 2021
SELL
Open market or private sale
$161,500 $32.3 p/Share
5,000 Reduced 18.79%
21,604 Common Stock
Oct 06 2021
BUY
Exercise of conversion of derivative security
$36,350 $7.27 p/Share
5,000 Added 15.82%
26,604 Common Stock
Oct 05 2021
SELL
Open market or private sale
$162,550 $32.51 p/Share
5,000 Reduced 18.79%
21,604 Common Stock
Oct 05 2021
BUY
Exercise of conversion of derivative security
$36,350 $7.27 p/Share
5,000 Added 15.82%
26,604 Common Stock
Sep 08 2021
SELL
Open market or private sale
$195,050 $39.01 p/Share
5,000 Reduced 18.79%
21,604 Common Stock
Sep 08 2021
BUY
Exercise of conversion of derivative security
$36,350 $7.27 p/Share
5,000 Added 15.82%
26,604 Common Stock
Sep 07 2021
SELL
Open market or private sale
$372,281 $39.71 p/Share
9,375 Reduced 30.26%
21,604 Common Stock
Sep 07 2021
BUY
Exercise of conversion of derivative security
$61,406 $6.55 p/Share
9,375 Added 23.23%
30,979 Common Stock
Aug 11 2021
SELL
Open market or private sale
$339,800 $33.98 p/Share
10,000 Reduced 31.64%
21,604 Common Stock
Aug 11 2021
BUY
Exercise of conversion of derivative security
$65,500 $6.55 p/Share
10,000 Added 24.04%
31,604 Common Stock
Aug 10 2021
SELL
Open market or private sale
$175,000 $35.0 p/Share
5,000 Reduced 18.79%
21,604 Common Stock
Aug 10 2021
BUY
Exercise of conversion of derivative security
$32,750 $6.55 p/Share
5,000 Added 15.82%
26,604 Common Stock
Jul 07 2021
SELL
Open market or private sale
$386,800 $38.68 p/Share
10,000 Reduced 31.64%
21,604 Common Stock
Jul 07 2021
BUY
Exercise of conversion of derivative security
$65,500 $6.55 p/Share
10,000 Added 24.04%
31,604 Common Stock
Jul 06 2021
SELL
Open market or private sale
$388,300 $38.83 p/Share
10,000 Reduced 31.64%
21,604 Common Stock
Jul 06 2021
BUY
Exercise of conversion of derivative security
$65,500 $6.55 p/Share
10,000 Added 24.04%
31,604 Common Stock
Jun 09 2021
SELL
Open market or private sale
$356,000 $35.6 p/Share
10,000 Reduced 31.64%
21,604 Common Stock
Jun 09 2021
BUY
Exercise of conversion of derivative security
$65,500 $6.55 p/Share
10,000 Added 24.04%
31,604 Common Stock
Jun 08 2021
SELL
Open market or private sale
$373,800 $37.38 p/Share
10,000 Reduced 31.64%
21,604 Common Stock

Also insider at

VCSA
Vacasa, Inc. Technology
CMC

Chad M Cohen

Chief Financial Officer
Seattle, WA

Track Institutional and Insider Activities on ADPT

Follow Adaptive Biotechnologies Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADPT shares.

Notify only if

Insider Trading

Get notified when an Adaptive Biotechnologies Corp insider buys or sells ADPT shares.

Notify only if

News

Receive news related to Adaptive Biotechnologies Corp

Track Activities on ADPT